Description
Market Report Coverage – In-Silico Drug Discovery Market
Market Segmentation
• Workflow – Discovery, Pre-Clinical Tests, and Clinical Trials
• Products – Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service
• Technology – Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies
• Software – Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software
• End User – Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users
Regional Segmentation
• North America: U.S., Canada
• Europe: Germany, France, Italy, U.K., Spain, Russia, and Rest-of- Europe
• Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World
Market Growth Drivers
• Rising Emphasis on Reduction in Medical Errors
• Technological Advancements in the Field of Computational Biology
• Integration of Blockchain Technology in Interoperability
• Rising Adoption of Cloud-Based Application for Drug Discovery
Market Challenges
• Lack of High Complexity Testing Centers
• Expensive In-Silico Drug Discovery Procedures and Decline in the Number of Approved Drugs
• High Capital Requirement Hampering the Expansion of Global Reach
Market Opportunities
• Massive Scope for Adoption of In-Silico Drug Discovery in Developing Nations
• Adoption of Artificial Intelligence in In-Silico Drug Discovery
Key Companies Profiled
Aragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC., Collaborative Drug Discovery Inc., Dassault Systemes, e-therapeutics plc., Evotec, Insilico Medicine, Ligand Pharmaceuticals Incorporated, Numerate, Inc., PerkinElmer Inc., Schrödinger, Inc., Selvita, Simulations Plus, Tracxn Technologies, WuXi AppTec
Key Questions Answered in this Report:
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Workflow (Discovery, Pre-Clinical Tests, and Clinical Trials)
o Products (Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service)
o Technology (Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies)
o Software (Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software)
o End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the major market drivers, restraints, and opportunities in the global in-silico drug discovery market?
• What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?
• How is each segment of the global in-silico drug discovery market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for in-silico drug discovery?
• Who are the leading players with significant offerings to the global in-silico drug discovery market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which in-silico drug discovery workflow type has the most promising growth?
• What are the major technologies that are employed in the global in-silico drug discovery market? Which is the dominating technology?
• Who are the primary end users of the global in-silico drug discovery market? Which is the fastest-growing end-user segment in the global in-silico drug discovery market?
• Who are the key manufacturers in the global in-silico drug discovery market, and what are their contributions? Also, what is the growth potential of each major in-silico drug discovery manufacturer?
• What is the scope of the global in-silico drug discovery market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which in-silico drug discovery technology and end user dominate these regions?
• What are the emerging trends in the global in-silico drug discovery market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the in-silico drug discovery regime?
• Which companies are anticipated to be highly disruptive in the future and why?
• Which regulatory procedures are required to unify the approval process for the emerging in-silico drug discovery market? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing in-silico drug discovery adoption in regular healthcare routines? How are these gaps being tackled?
Market Overview
In-silico drug discovery methods can help in identifying drug targets via bioinformatics tools. In addition, the methods can also be used to analyze the target structures for possible binding active sites. The use of computational methods and computers permeates all aspects of drug discovery and drug design. The methods are facilitating the access of massive amounts of data generated and transforming the extensive complex biological data into useful knowledge for the drug discovery process. These computational tools offer the advantage of delivering new drug candidates more quickly and at a lower cost.
Our healthcare experts have found the in-silico drug discovery market to be one of the stable markets, and the global market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031 and is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031.
Factors fueling the growth of the market include the rising emphasis on reduction in medical errors, technological advancements in the field of computational biology, and the rising adoption of cloud-based applications in drug discovery procedures. New drug compounds have been developed using computational methods successfully. The developments in computational biology have eased the data analytics and analysis phases of sequencing and have resulted in fewer turnaround times and greater accuracy.
Within the research report, the market has been segmented based on workflow, product, technology, software type, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as artificial intelligence.
Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Related reports: Global E-discovery Market Market Analysis and Forecast Report 2030
Table of Contents
1 Markets
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Global In-Silico Drug Discovery Market Size and Forecast
1.3 Global In-Silico Drug Discovery Market Size and Forecast – Realistic, Optimistic, and Conservative Growth Scenario
1.3.1 Realistic Growth Scenario
1.3.2 Conservative Growth Scenario
1.3.3 Optimistic Growth Scenario
1.4 Current Global In-Silico Drug Discovery Market Landscape
1.4.1 Market Availability for In-Silico Drug Discovery
1.4.2 In-Silico Drug Discovery Market Technology Trends
1.5 Market Dynamics
1.5.1 Overview
1.5.2 Impact Analysis
1.5.3 Market Drivers
1.5.3.1 Rising Emphasis on Reduction in Medical Errors
1.5.3.2 Technological Advancements in the Field of Computational Biology
1.5.3.3 Integration of Blockchain Technology in Interoperability
1.5.3.4 Rising Adoption of Cloud-Based Application for Drug Discovery
1.5.4 Market Restraints
1.5.4.1 Lack of High Complexity Testing Centers
1.5.4.2 Expensive In-Silico Drug Discovery Procedures and Decline in the Number of Approved Drugs
1.5.4.3 High Capital Requirement Hampering the Expansion of Global Reach
1.5.5 Market Opportunities
1.5.5.1 Massive Scope for Adoption of In-Silico Drug Discovery in Developing Nations
1.5.5.2 Adoption of Artificial Intelligence in In-Silico Drug Discovery
1.6 COVID-19 Impact on Global In-Silico Drug Discovery Market
1.6.1 Overview
1.6.2 Impact on the Market Growth
1.6.3 Impact on Clinical Trial
1.6.4 Impact on R&D
1.7 Competitive Landscape
1.7.1 Acquisitions
1.7.2 Synergistic Activities
1.7.3 Product Launches and Upgradations
1.7.4 Business Expansion
1.7.5 Patent Approval, Fundings, Investments, and Marketing Strategy
1.7.6 Market Share Analysis
1.7.7 Growth Share Analysis
1.8 Industry Insights
1.8.1 Regulatory Framework in North America
1.8.2 Regulatory Framework in Europe
1.8.3 Regulatory Framework in Asia-Pacific
1.9 Patent Analysis
1.9.1 Patent Filing Trend
2 Products
2.1 Overview
2.1.1 Software
2.1.2 Software-as-a-Service (Cloud)
2.1.3 Consultancy-as-a-Service
3 Workflow
3.1 Overview
3.2 Discovery
3.2.1 Target Identification
3.2.1.1 Bioinformatics
3.2.1.2 Reverse Docking
3.2.1.3 Protein Structure Prediction
3.2.2 Target Validation
3.2.3 Lead Discovery
3.2.3.1 Library Design
3.2.3.2 Pharmacophore
3.3 Pre-Clinical Tests
3.4 Clinical Trials
4 Software Type
4.1 Overview
4.1.1 Molecular Modeling and De Novo Drug Design Software
4.1.2 Pharmacophore Modeling Software
5 Technology
5.1 Overview
5.1.1 Artificial Intelligence
5.1.1.1 Computational Methods Used by Advanced AI Companies
5.1.1.2 Use of Artificial Intelligence to Combat COVID-19 Pandemic
5.1.2 Graphics Processing Unit
5.1.3 Other Technologies
5.1.3.1 In-Silico Fishing
5.1.3.2 RNN for Drug Design
6 End-User
6.1 Overview
6.1.1 Contract Research Organizations
6.1.2 Pharmaceutical and Biopharmaceutical Companies
6.1.3 Academic and Research Institutes
6.1.4 Other End Users (Hospitals and Other Care Facilities)
7 Region
7.1 Overview
7.2 North America
7.2.1 North America In-Silico Drug Discovery Market (by Technology)
7.2.2 U.S.
7.2.3 Canada
7.3 Europe
7.3.1 Europe In-Silico Drug Discovery Market (by Technology)
7.3.2 Germany
7.3.3 U.K.
7.3.4 France
7.3.5 Italy
7.3.6 Russia
7.3.7 Spain
7.3.8 Rest-of-Europe
7.4 Asia-Pacific (APAC)
7.4.1 Asia-Pacific In-Silico Drug Discovery Market (by Technology)
7.4.2 China
7.4.3 India
7.4.4 Japan
7.4.5 Australia
7.4.6 South Korea
7.4.7 Rest-of-Asia-Pacific
7.5 Latin America (LATAM)
7.5.1 Latin America In-Silico Drug Discovery Market (by Technology)
7.5.2 Brazil
7.5.3 Mexico
7.5.4 Rest-of-Latin America
7.6 Rest-of-the-World (RoW)
7.6.1 Rest-of-the-World In-Silico Drug Discovery Market (by Technology)
8 Markets – Competitive Benchmarking & Company Profiles
8.1 Competitive Benchmarking
8.2 Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
8.2.1 Company Overview
8.2.2 Role of Aragen Life Sciences Pvt. Ltd. in the Global In-Silico Drug Discovery Market
8.2.3 SWOT Analysis
8.3 Curia Global, Inc. (Albany Molecular Research Inc.)
8.3.1 Company Overview
8.3.2 Role of Curia Global, Inc. in the Global In-Silico Drug Discovery Market
8.3.3 SWOT Analysis
8.4 Certara, USA.
8.4.1 Company Overview
8.4.2 Role of Certara, USA. in the Global In-Silico Drug Discovery Market
8.4.3 SWOT Analysis
8.5 Charles River
8.5.1 Company Overview
8.5.2 Role of Charles River in the Global In-Silico Drug Discovery Market
8.5.3 Financials
8.5.4 SWOT Analysis
8.6 Chemical Computing Group ULC. (CCG)
8.6.1 Company Overview
8.6.2 Role of Chemical Computing Group ULC. in the Global In-Silico Drug Discovery Market
8.6.3 SWOT Analysis
8.7 Collaborative Drug Discovery Inc. (CDD)
8.7.1 Company Overview
8.7.2 Role of Collaborative Drug Discovery Inc., in the Global In-Silico Drug Discovery Market
8.7.3 SWOT Analysis
8.8 Dassault Systemes
8.8.1 Company Overview
8.8.2 Role of Dassault Systemes in the Global In-Silico Drug Discovery Market
8.8.3 Financials
8.8.4 Key Insights About Financial Health of the Company
8.8.5 SWOT Analysis
8.9 e-therapeutics plc.
8.9.1 Company Overview
8.9.2 Role of e-therapeutics plc. in the Global In-Silico Drug Discovery Market
8.9.3 Financials
8.9.4 Key Insights About Financial Health of the Company
8.9.5 SWOT Analysis
8.1 Evotec (Cyprotex)
8.10.1 Company Overview
8.10.2 Role of Evotec in the Global In-Silico Drug Discovery Market
8.10.3 Financials
8.10.4 Key Insights About Financial Health of the Company
8.10.5 SWOT Analysis
8.11 Insilico Medicine
8.11.1 Company Overview
8.11.2 Role of Insilico Medicine in the Global In-Silico Drug Discovery Market
8.11.3 SWOT Analysis
8.12 Ligand Pharmaceuticals Incorporated (Icagen, Inc.)
8.12.1 Company Overview
8.12.2 Role of Ligand Pharmaceuticals Incorporated in the Global In-Silico Drug Discovery Market
8.12.3 Financials
8.12.4 Key Insights About Financial Health of the Company
8.12.5 SWOT Analysis
8.13 Numerate, Inc.
8.13.1 Company Overview
8.13.2 Role of Numerate Inc. in the Global In-Silico Drug Discovery Market
8.13.3 SWOT Analysis
8.14 PerkinElmer Inc.
8.14.1 Company Overview
8.14.2 Role of PerkinElmer Inc., in the Global In-Silico Drug Discovery Market
8.14.3 Financials
8.14.4 Key Insights About Financial Health of the Company
8.14.5 SWOT Analysis
8.15 Schrödinger, Inc.
8.15.1 Company Overview
8.15.2 Role of Schrödinger, Inc. in the Global In-Silico Drug Discovery Market
8.15.3 Financials
8.15.4 Key Insights About Financial Health of the Company
8.15.5 SWOT Analysis
8.16 Selvita
8.16.1 Company Overview
8.16.2 Role of Selvita in the Global In-Silico Drug Discovery Market
8.16.3 SWOT Analysis
8.17 Simulations Plus
8.17.1 Company Overview
8.17.2 Role of Simulations Plus in the Global In-Silico Drug Discovery Market
8.17.3 Financials
8.17.4 Key Insights About Financial Health of the Company
8.17.5 SWOT Analysis
8.18 Tracxn Technologies (Novo Informatics Pvt. Ltd.)
8.18.1 Company Overview
8.18.2 Role of Tracxn Technologies in the Global In-Silico Drug Discovery Market
8.18.3 SWOT Analysis
8.19 WuXi AppTec
8.19.1 Company Overview
8.19.2 Role of WuXi AppTec in the Global In-Silico Drug Discovery Market
8.19.3 Financials
8.19.4 Key Insights About Financial Health of the Company
8.19.5 SWOT Analysis
List of Figures
Figure 1: Cost-Benefit Analysis between Conventional and In-Silico Method
Figure 2: Global In-Silico Drug Discovery Market (Realistic and Optimistic Scenario), $Million, 2020-2031
Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global In-Silico Drug Discovery Market
Figure 4: Share of Key Market Strategies and Developments, January 2018–January 2022
Figure 5: Global In-Silico Drug Discovery Market Snapshot, $Million, 2020-2031
Figure 6: Global In-Silico Drug Discovery Market (by Workflow), $Million, 2020 Vs. 2031
Figure 7: Global In-Silico Drug Discovery Market (by Product), $Million, 2020 Vs. 2031
Figure 8: Global In-Silico Drug Discovery Market (by Software), $Million, 2020 Vs. 2031
Figure 9: Global In-Silico Drug Discovery Market Snapshot
Figure 10: Global In-Silico Drug Discovery Market Research Methodology
Figure 11: Global In-Silico Drug Discovery Market: Segmentation
Figure 12: Global In-Silico Drug Discovery Market Incremental Opportunity, $Million, 2020-2031
Figure 13: Global In-Silico Drug Discovery Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
Figure 14: Global In-Silico Drug Discovery Market Size and Growth Potential (Conservative Scenario), $Million, 2020-2031
Figure 15: Global In-Silico Drug Discovery Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
Figure 16: Various Steps of In-Silico Drug Discovery Process
Figure 17: Impact Analysis
Figure 18: Summary of Drug Discovery Process Overlayed with Computational Approach and Methods Used for In-Silico Drug Design
Figure 19: Number of Approved Drugs from 2015-2019
Figure 20: Impact of COVID-19 on In-Silico Drug Discovery Market
Figure 21: Share of Key Developments and Strategies, January 2018-January 2022
Figure 22: Share of Acquisitions (by Company), January 2018-January 2021
Figure 23: Synergistic Activities Share (by Company), January 2018-January 2022
Figure 24: Product Launches and Upgradations (by Company), January 2018–December 2021
Figure 25: Share of Business Expansion Activities (by Company), January 2018-December 2021
Figure 26: Market Share Analysis for Global In-Silico Drug Discovery Market, $Million, 2019 and 2020
Figure 27: Growth Share Analysis of Global In-Silico Drug Discovery Market (by Technology), 2020-2031
Figure 28: Year-Wise Analysis of Patents Related to In-Silico Drug Discovery
Figure 29: Share of Global In-Silico Drug Discovery Market (by Product), $Million, 2020 and 2031
Figure 30: Global In-Silico Drug Market (Software), $Million, 2020-2031
Figure 31: Global In-Silico Drug Market (Software-as-a-Service), $Million, 2020-2031
Figure 32: Global In-Silico Drug Discovery Market (Consultancy-as-a-Service), $Million, 2020-2031
Figure 33: Global In-Silico Drug Discovery Market (by Workflow)
Figure 34: Global In-Silico Drug Discovery Market (by Workflow), $Million, 2020-2031
Figure 35: Global In-Silico Drug Discovery Market (Target Identification), $Million, 2020-2031
Figure 36: Global In-Silico Drug Discovery Market (Bioinformatics), $Million, 2020-2031
Figure 37: Global In-Silico Drug Discovery Market (Reverse Docking), $Million, 2020-2031
Figure 38: Global In-Silico Drug Discovery Market (Protein Structure Prediction), 2020-2031
Figure 39: Global In-Silico Drug Discovery Market (Target Validation), $Million, 2020-2031
Figure 40: Global In-Silico Drug Discovery Market (Lead Discovery), $Million, 2020-2031
Figure 41: Global In-Silico Drug Discovery Market (Library Design), $Million, 2020-2031
Figure 42: Global In-Silico Drug Discovery Market (Pharmacophore), $Million, 2020-2031
Figure 43: Global In-Silico Drug Discovery Market (Pre-Clinical Tests), $Million, 2020-2031
Figure 44: Global In-Silico Drug Discovery Market (Clinical Trials), $Million, 2020-2031
Figure 45: Global In-Silico Drug Discovery Market (by Software Type), $Million, 2020 and 2031
Figure 46: Global In-Silico Drug Discovery Market (Molecular Modeling and De Novo Drug Design Software), 2020-2031
Figure 47: Global In-Silico Drug Market (Pharmacophore Modeling Software), $Million, 2020-2031
Figure 48: Share of Global In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031
Figure 49: Global In-Silico Drug Discovery Market (Artificial Intelligence), $Million, 2020-2031
Figure 50: Global In-Silico Drug Discovery Market (Graphics Processing Unit), $Million, 2020-2031
Figure 51: Global In-Silico Drug Discovery Market (Other Technologies), $Million, 2020-2031
Figure 52: Evolutionary De Novo Drug Design Using RNN
Figure 53: Global In-Silico Drug Discovery Market (by End User), $Million, 2020 and 2031
Figure 54: Global In-Silico Drug Discovery Market (Contract Research Organizations), $Million, 2020-2031
Figure 55: Global In-Silico Drug Discovery Market (Pharmaceutical and Biopharmaceutical Companies), $Million, 2020-2031
Figure 56: Global In-Silico Drug Discovery Market (Academic and Research Institutes), $Million, 2020-2031
Figure 57: Global In-Silico Drug Discovery Market (Oher End Users), $Million, 2020-2031
Figure 58: Global In-Silico Drug Discovery Market (by Region), $Million, 2020-2031
Figure 59: Share of North America In-Silico Drug Discovery Market Revenue (by Country), $Million, 2020 and 2031
Figure 60: North America: Market Dynamics
Figure 61: North America In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031
Figure 62: U.S. In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 63: Canada In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 64: Europe In-Silico Drug Discovery Market (by Country), $Million, 2020 and 2031
Figure 65: Europe: Market Dynamics
Figure 66: Europe In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031
Figure 67: Germany In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 68: U.K. In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 69: France In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 70: Italy In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 71: Russia In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 72: Spain In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 73: Rest-of-Europe In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 74: APAC: Market Dynamics
Figure 75: Asia-Pacific In-Silico Drug Discovery Market (by Country), $Million, 2020 and 2031
Figure 76: Asia-Pacific In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031
Figure 77: China In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 78: India In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 79: Japan In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 80: Australia In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 81: South Korea In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 82: Rest-of-Asia-Pacific In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 83: LATAM: Market Dynamics
Figure 84: Latin America In-Silico Drug Discovery Market (by Country), $Million 2020 and 2031
Figure 85: Latin America In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031
Figure 86: Brazil In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 87: Mexico In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 88: Rest-of-Latin America In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 89: Rest-of-the-World In-Silico Drug Discovery Market, $Million, 2020-2031
Figure 90: Rest-of-the-World In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031
Figure 91: Share of Key Company Profiles
Figure 92: Product Portfolio: Aragen Life Sciences Pvt. Ltd.
Figure 93: Aragen Life Sciences Pvt. Ltd.: SWOT Analysis
Figure 94: Curia Global, Inc.: Product Portfolio
Figure 95: Curia Global, Inc.: SWOT Analysis
Figure 96: Certara, USA.: Product Portfolio
Figure 97: Certara, USA.: SWOT Analysis
Figure 98: Charles River.: Product Portfolio
Figure 99: Charles River: Overall Financials, $Million, 2018-2020
Figure 100: Charles River: Revenue (by Segment), $Million, 2018-2020
Figure 101: Charles River: SWOT Analysis
Figure 102: Chemical Computing Group ULC.: Product Portfolio
Figure 103: Chemical Computing Group ULC.: SWOT Analysis
Figure 104: Collaborative Drug Discovery Inc. (CDD): Overall Product Portfolio
Figure 105: Collaborative Drug Discovery Inc. (CDD): SWOT Analysis
Figure 106: Dassault Systemes: Product Offerings
Figure 107: Dassault Systemes: Overall Financials, $Million, 2018-2020
Figure 108: Dassault Systemes.: R&D Expenditure, $Million, 2018-2020
Figure 109: Dassault Systemes: SWOT Analysis
Figure 110: e-therapeutics plc.: Product Portfolio
Figure 111: e-therapeutics plc.: Overall Financials, $Million, 2019-2021
Figure 112: e-therapeutics plc.: R&D Expenditure, $Million, 2019-2021
Figure 113: e-therapeutics plc.: SWOT Analysis
Figure 114: Evotec: Product Offerings
Figure 115: Evotec: Overall Financials, $Million, 2018-2020
Figure 116: Evotec: R&D Expenditure, $Million, 2018-2020
Figure 117: Evotec: SWOT Analysis
Figure 118: Insilico Medicine: Product Portfolio
Figure 119: Insilico Medicine: SWOT Analysis
Figure 120: Ligand Pharmaceuticals Incorporated: Overall Product Portfolio
Figure 121: Ligand Pharmaceuticals Incorporated: Overall Financials, $Million, 2018-2020
Figure 122: Ligand Pharmaceuticals Incorporated: R&D Expenditure, $Million, 2018-2020
Figure 123: Ligand Pharmaceuticals, Inc: SWOT Analysis
Figure 124: Numerate Inc.: Overall Product Portfolio
Figure 125: Numerate Inc.: SWOT Analysis
Figure 126: PerkinElmer Inc.: Product Portfolio for Global In-Silico Drug Discovery Market
Figure 127: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
Figure 128: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 129: PerkinElmer Inc.: R&D Expenditure, $Million, 2018-2020
Figure 130: PerkinElmer Inc.: SWOT Analysis
Figure 131: Schrödinger, Inc.: Product Portfolio for Global In-Silico Drug Discovery Market
Figure 132: Schrödinger, Inc.: Overall Financials, $Million, 2018-2020
Figure 133: Schrödinger, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 134: Schrödinger, Inc.: SWOT Analysis
Figure 135: Selvita: Product Portfolio
Figure 136: Selvita: SWOT Analysis
Figure 137: Simulations Plus: Product Portfolio
Figure 138: Simulations Plus.: Overall Financials, $Million, 2019-2021
Figure 139: Simulations Plus: R&D Expenditure, $Million, 2019-2021
Figure 140: Simulations Plus: SWOT Analysis
Figure 141: Tracxn Technologies: Product Portfolio
Figure 142: Tracxn Technologies Company: SWOT Analysis
Figure 143: WuXi AppTec: Product Portfolio
Figure 144: WuXi AppTec.: Overall Financials, $Million, 2018-2020
Figure 145: WuXi AppTec: R&D Expenditure, 2018-2020
Figure 146: WuXi AppTec: SWOT Analysis
List of Tables
Table 1: List of Few Cloud-Based Solutions Used for VS and Target Fishing
Table 2: COVID-19 Impact on Global In-Silico Drug Discovery Market
Table 3: Approved Products Launch by Various Manufacturers During COVID-19
Table 4: List of Companies using AI for COVID-19 Treatment
Table 5: Impact of COVID-19 on Drug Trial
Table 6: Regulatory Framework for In-Silico Drug Discovery Market in North America
Table 7: Regulatory Framework for In-Silico Drug Discovery Market in Europe
Table 8: Regulatory Framework for In-Silico Drug Discovery Market in Asia-Pacific
Table 9: List of Advanced AI Companies Using Computational Methods
Table 10: Application of AI for COVID-19 Drug Repurposing
Reviews
There are no reviews yet.